Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.56 |
| ▸ | WNT3A | P56704 | 7/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727479 | 0.91 | CTNNB1 (0.68) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 | |
| SCHEMBL1183664 | 0.87 | ATM (0.47) | PRKCICTNNB1WNT3ARAB9ANPC1 | |
| SCHEMBL14044259 | 0.85 | PRKCI (0.58) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 | |
| SCHEMBL1091802 | 0.84 | ATM (0.69) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 | |
| SCHEMBL1182701 | 0.84 | PRKCI (0.57) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 | |
| SCHEMBL627847 | 0.81 | ATM (0.70) | CTNNB1WNT3ARAB9ANPC1ATM | |
| SCHEMBL11022828 | 0.81 | HPGD (0.70) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 | |
| SCHEMBL4260152 | 0.81 | PKM (0.70) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 | |
| SCHEMBL15088740 | 0.81 | CTNNB1 (0.60) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 | |
| SCHEMBL11022359 | 0.81 | PRKCI (0.66) | PRKCICTNNB1WNT3ATAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704105-B9 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-3704105-B1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2024-10-16 | — | — | EP | disclosed |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| EP-1507530-B1 | DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| US-6916826-B2 | Substituted imidazo[1,2-a]pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6861437-B2 | Substituted imidazo [1,2-a] pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1381363-A1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-21 | — | — | EP | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | MUTEL VINCENT (FR) | 2003-11-13 | — | — | US | disclosed |
| US-6596731-B2 | An imidazo(1,2-a)pyridine derivative useful for treating chronical or acute neurological disorders, cognitive disorders and memory deficits | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | disclosed |
| WO-2002092086-A1 | IMIDAZO (1,2-A)-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
| EP-1065204-B1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6303628-B1 | FOR THE TREATMENT OF A MEDICAL CONDITION IN WHICH PROSTAGLANDINS ARE IMPLICATED AS PATHOGENS IN MAMMALS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| EP-1065204-A1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | GRM5, GRM1, GRIK5 | PRKCI 2695/4885CTNNB1 4737/4885WNT3A 3920/4885 |
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | PRKCI 3680/4885CTNNB1 4159/4885WNT3A 4202/4885 |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | PRKCI 1291/4885CTNNB1 2154/4885WNT3A 1276/4885 |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NRDC, PGLS | PRKCI 2040/4885CTNNB1 3726/4885WNT3A 3608/4885 |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, MRPL21, NQO1 | PRKCI 3680/4885CTNNB1 4159/4885WNT3A 4202/4885 |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | GRM5, GRM1, GRIK5 | PRKCI 2695/4885CTNNB1 4737/4885WNT3A 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.